drugset
drugset / Trial / NCT06031584

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

NCT06031584 ↗

Phase 1/2 Recruiting 42 enrolled Sichuan Baili Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Phase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors. Phase II: To explore the efficacy of BL-M07D1 in patients with a variety of solid tumors including locally advanced or metastatic HER2-positive/low-expressing urinary and gastrointestinal tumors.

Timeline

Start
2024-01-19
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BL-M07D1 Unknown — Intravenous

Indications

No indication recorded.